Table 1.
Baseline characteristics of patients with and without CMV infection.
Table 2.
Clinical characteristics of patients who received intravenous GCV and oral VGCV.
Table 3.
Clinical characteristics between intravenous GCV and oral VGCV.
Fig 1.
Rates of CMV reinfection after preemptive treatments.
Relapsed secondary CMV infection rates in the intravenous GCV and in the oral VGCV groups were 14.8% and 4.5%.
Fig 2.
(A) Graft survival and (B) patient survival stratified according to antiviral agent use.
The 1-year and 2-year survival rates of patients with CMV infection and patients without CMV infection were 86.7%% vs. 92.3% and 84.2% vs. 92.3%, respectively (P = 0.218). With respect to antiviral agents, the 1-year and 2-year survival rates of the intravenous GCV and the oral VGCV groups were 95.5% vs. 83.6% and 86.8% vs. 83.6%, respectively (P = 0.365)